

www.FirstRanker.comational brown FirstRanker.com

MEDICAL ONCOLOGY

PAPER-III

Time: 3 hours MED ONCO/J/19/17/III

Max. Marks:100

Important Instructions:

- Attempt all questions in order.
- Each question carries 10 marks.
- Read the question carefully and answer to the point neatly and legibly.
- Do not leave any blank pages between two answers.
- Indicate the question number correctly for the answer in the margin space.
- Answer all the parts of a single question together.
- Start the answer to a question on a fresh page or leave adequate space between two answers.
- Draw table/diagrams/flowcharts wherever appropriate.

Write short notes on:

1.	a) Staging of neuroblastoma.b) Paraneoplastic syndromes associated with neuroblastoma.c) Management of stage IV neuroblastoma.	3+3+4
2.	a) Treatment of low risk gestational trophoblastic neoplasm.b) Mixed Mullerian tumour (carcinosarcoma) of uterus.c) Sertoli-Leydig cell tumour of ovary.	4+3+3
3.	 a) How will you evaluate a solitary, large supratentorial brain SOL in a 60-year-old male presenting with neuro-cognitive decline? b) Management of newly diagnosed primary CNS lymphoma. 	5+5
	b) Management of Newly diagnosed primary CNS lymphoma.	
4.	 a) Role of autologous PBSCT in Non-Hodgkin's Lymphoma (NHL). b) Conditioning regimes for autologous PBSCT in NHL. c) Acute GVHD (Graft vs Host disease) 	3+3+4
5.	 a) Indications of treatment in chronic lymphocytic leukemia (CLL). b) Treatment options in newly diagnosed CLL. c) Management of hairy cell leukemia. 	3+3+4
6.	a) How do you approach abdominal mass on 5-year-old child?b) Staging of Wilms' tumour.c) Management of bilateral Wilms' tumour.	4+3+3

P.T.O.



JUNE 2019

www.FirstRanker.comational bywww.FirstRanker.com

MEDICAL ONCOLOGY

PAPER-III

7.	a) WHO classification of Myelodysplastic syndrome (MDS).b) Prognostic scoring systems in MDS.c) 5q deletion syndrome.	4+3+3
8.	 a) Diagnostic criteria for Waldenstrom Macroglobulinemia (WM). b) International Prognostic scoring staging system in WM. c) Treatment of newly diagnosed WM. 	3+3+4
9.	a) Management of Ph positive ALL.b) Role of MRD in ALL treatment.c) Ph like ALL and its management.	4+3+3
10.	a) Systemic therapy for medullary thyroid cancer.b) Management of radioiodine refractory papillary thyroid carcinoma.	4+3+3

c) Anaplastic thyroid carcinoma.

Man Kitest Banker com